TherapeuticsMD (TXMD) Return on Capital Employed (2011 - 2026)

TherapeuticsMD has reported Return on Capital Employed for 15 years, with the latest figure at 11.72% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 562.0% year-over-year to 11.72%; the trailing twelve-month figure through Mar 2026 stood at 11.72% (up 562.0% YoY), and the FY2025 full-year result was 13.12%, up 390.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 11.72%, up from 13.15% in the prior quarter.
• The five-year high for Return on Capital Employed was 446.57% in Q2 2022, with the low at 21.28% in Q4 2023.
• Historically, Return on Capital Employed has averaged 50.06% across 5 years, with a median of 11.16% in 2025.
• Annual changes were most pronounced in 2022 — Return on Capital Employed surged 52966 bps — and 2023, when it sank 37849 bps.
• TherapeuticsMD's Return on Capital Employed stood at 1.82% in 2022, then sank by 1268 bps to 21.28% in 2023, then gained by 21 bps to 16.8% in 2024, then increased by 22 bps to 13.15% in 2025, then increased by 11 bps to 11.72% in 2026.
• The last three Return on Capital Employed figures came in at 11.72% (Q1 2026), 13.15% (Q4 2025), and 10.37% (Q3 2025), per Business Quant data.